Targeting Protein Kinase C in Glioblastoma Treatment

Targeting Protein Kinase C in Glioblastoma Treatment

Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor and is associated with a poor prognosis. Despite the use of combined treatment approaches, recurrence is almost inevitable and survival longer than 14 or 15 months after diagnosis is low. It is therefore necessary to identify...

Full description

Bibliographic Details
Main Authors: Noelia Geribaldi-Doldán, Irati Hervás-Corpión, Ricardo Gómez-Oliva, Samuel Domínguez-García, Félix A. Ruiz, Irene Iglesias-Lozano, Livia Carrascal, Ricardo Pardillo-Díaz, José L. Gil-Salú, Pedro Nunez-Abades, Luis M. Valor, Carmen Castro
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Biomedicines
Subjects:
glioblastoma
protein kinase C
glioma stem cells
neurogenesis
neural stem cells
temozolomide
Online Access:https://www.mdpi.com/2227-9059/9/4/381

Internet

https://www.mdpi.com/2227-9059/9/4/381

Similar Items